At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 386 enrolled
Drug / intervention
Aliskiren Hydrochlorothiazide +1 moredrug
Likely dose
Aliskiren Hydrochlorothiazide 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
In Brief
A Phase 4 clinical trial evaluating Aliskiren Hydrochlorothiazide and Ramipril for Hypertension. Completed, enrolled 386 participants across 6 sites.
Detailed Summary
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedOct 2008
Primary CompletionMar 2009
TodayJul 2026
First PostedOct 15, 2008
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.7 years ago
Interventions
Aliskiren Hydrochlorothiazidedrug
Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
Ramiprildrug
Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks